IMRN - Immuron Ltd ADR

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.

52W High

$2.87

52W Low

$1.50

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.50

Valuation

As of 2024-12-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.77

EV/Revenue (<3 favorable)

1.76

P/S (TTM) (<3 favorable)

1.46

P/B (<3 favorable)

2.03

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

0.34%

Shares Outstanding

5,728,600

Float

231,477,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-12-31 (Overview)

Revenue (TTM)

7,287,000

Gross Profit (TTM)

4,765,100

EPS (TTM)

-0.59

Profit Margin (>10% good)

-0.72%

Operating Margin (TTM) (higher better)

-0.87%

ROE (TTM) (>15% strong)

-0.51%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.29

Momentum

Bearish momentum

Value

0.0508

0.0466

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025